Doximity upgraded to Overweight from Neutral at Piper Sandler

Piper Sandler upgraded Doximity (DOCS) to Overweight from Neutral with a price target of $78, up from $31, after the company reported a large Q3 revenue and adjusted EBITDA beat, with record prescriber engagement and “encouraging bookings momentum.” The analyst, who believes “double-digit growth is back for good,” tells investors “we did not know when to walk away from our Neutral rating, but we know when to run.”